Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZURA
Strong SellSinkerZura Bio Limited · Healthcare · United States · $548M · Avg Vol: $7M/d
16
StockRankGet insider-trade alerts
Q
29
V
28
M
40
P/E (TTM)
—
ROE
-51.0%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 12.5M | — |
| EPS | -3.48 | -0.96 | -0.60 | -1.06 | — | -1.12 | -0.77 | -0.58 | — |
| Shares | 94.9M | 94.9M | 65.3M | 73.7M | -22.3% | 95.8M | — | — | — |
| Debt | 7.8M | — | — | — | — | — | — | — | — |
| Equity | -32.1M | 59.3M | 146.8M | 101.5M | 30.8% | — | — | — | — |
| Op CF | -1.2M | -15.1M | -28.1M | -64.8M | — | -77.5M | — | — | — |
| Inv CF | -12.0M | -8.0M | -5.1M | -0.1M | — | — | — | — | — |
| Fin CF | 14.8M | 121.3M | 109.8M | -2.2M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-2.9%
SMA 50SMA 200
Close
$5.38
RSI (14)
43.6
52W High
$7.44
From 52W High
0.7%
SCORE BREAKDOWN
Quality
29
ROIC
-80.3%9.4
ROE
-51.0%17.9
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-63.8%4.7
Piotroski
13.8
Int. Cover
—N/A
D/E Ratio
0.00x98.1
Current Ratio
12.90x91.2
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-3.9x25.0
P/FCF
—N/A
P/B
3.0x46.1
P/S
—N/A
Div Yield
—N/A
Momentum
40
52W High %
72%55.7
RS 6M
-36%23.4
SMA 50/200
1.06x69.1
EPS Rev 4W
-5.4%12.8
EPS Rev 12W
—N/A
EPS Improve
+48%53.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$548M
P/E (Forward)
-10.7x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZURA | Zura Bio Limited(you) | $548M | 16 | Strong Sell |
| ALT | Altimmune, Inc. | $605M | 16 | Strong Sell |
| EDIT | Editas Medicine, Inc. | $485M | 14 | Strong Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 16 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 16 | Strong Sell |
| MPLT | MapLight Therapeutics, Inc. | $584M | 21 | Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 10 | Strong Sell |
| DNA | Ginkgo Bioworks Holdings, Inc. | $469M | 20 | Sell |
| RLMD | Relmada Therapeutics, Inc. | $462M | 20 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%